Frequency of metabolic syndrome in Paget's disease of bone

Objective: Our aim is to verify the prevalance of metabolic syndrome (MetS) in Paget’s disease of bone (PDB) and to reveal the relationship between metabolic syndrome and bone alkaline phosphatase levels (BAP).
Material and Methods: Twenty three patients with PDB and 30 healthy subjects matched with age, sex, and body mass index (BMI) were recruited from the outpatient clinics of Endocrinology. The International Diabetes Federation (IDF)-2006 metabolic syndrome criterias were used for the evaluation of all participants. PDB group and control group were compared in terms of metabolic syndrome and metabolic components of metabolic syndrome and bone mineral metabolism parameters.
Results: When the two groups were compared in terms of weight, waist circumference, BMI and systolic blood pressure (SBP) (p=0.09, p=0.644, p=0.78, p=0.058 recpectively), no statistically significant difference was found.
The frequency of impaired fasting glucose (IFG) and Diabetes mellitus (DM) was determined as %30 (7/23) in the PDB group. There were no patients in the control group with IFG and DM diagnosis.The frequency of IFG and DM was statistically higher in the PDB group than controls (p=0.002). The frequency of MetS was statistically higher in the PDB group than the controls. (73.91%, (17/23) vs.30% (9/30);p<0.01).There was a correlation between ALP level and hypertension medication (p=0.0045, r=0.27).
Conclusion: Patients with PDB seem to have metabolic syndrome more frequently, these patients also should be monitored for metabolic syndrome.

Kemiðin Paget Hastalýðýnda Metabolik Sendrom Sýklýðý

Amaç: Kemiðin Paget hastalýðýnda, metabolik sendrom prevalansýný saptamayý ve metabolik sendrom ile kemik spesifik ALP seviyesi arasýndaki iliþkiyi belirlemeyi amaçladýk.
Materyal ve Metod: Kemiðin Paget hastalýðýna sahip 23 hasta ve 30 yaþ, cins ve vücut kitle indeksi (VKÝ) uyumlu kontrol grubu çalýþmaya dahil edildi.Tüm katýlýmcýlar Uluslararasý Diyabet Federasyonu (IDF)-2006 metabolik sendrom taný kriterleri kullanýlarak deðerlendirildi. Kemik ve mineral metabolizma parametreleri deðerlendirildi. Paget hasta grubu ve kontrol grubu metabolik sendromun metabolik komponentleri ve kemik mineral metabolizma parametreleri açýsýndan karþýlaþtýrýldý.
Bulgular: Kilo, bel çevresi, VKÝ ve sistolik kan basýncý (SKB) açýsýndan her iki grup arasýnda istatistiksel olarak anlamlý fark yoktu (sýrasýyla p=0.09, p=0.644, p=0.78, p=0.058). Paget hasta grubunda bozulmuþ açlýk glukozu (BAG) ve diyabetes mellitus (DM) sýklýðý %30 (7/23) olarak bulundu.Kontrol grubunda BAG ve DM tanýsý alan hasta yoktu.Her iki grup BAG ve DM sýklýðý açýsýndan karþýlaþtýrýldýðýnda, Paget hasta grubunda BAG ve DM sýklýðýnýn istatistiksel olarak daha fazla olduðu saptandý (p=0.002). Paget hasta grubunda metabolik sendrom sýklýðý % 73.91( 17/23) iken, kontrol grubunda metabolik sendrom sýklýðý %30 (9/30) olarak bulundu. Paget hasta grubunda metabolik sendrom sýklýðý kontrol grubuna göre istatistiksel olarak daha yüksek saptandý (p<0.01). ALP düzeyleri ile hipertansiyon tedavisi arasýnda anlamlý korelasyon gözlendi (p=0.0045, r=0.27)
Sonuç: Kemiðin Paget hastalýðýna sahip hastalarda metabolik sendrom sýk görülmektedir. Dolayýsýyla hastalarýn metabolik sendrom ve iliþkili olduðu kardiyovasküler hastalýklar açýsýndan da izlenmesi gerekmektedir. (SETB-2021-07-225)